HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 22, No 07, July 2018 – Water management- Technologies for biotech and pharmaceutical industries       » Why sunshine improves mood and makes us smarter       » SGD110 million lab to create healthier foods and sustainable biochemicals       » Entries open for the USD170,000 Ryman Prize       » Could the eye be the window to brain degeneration?       » High vitamin D levels linked to lower cholesterol in children      
NEWS CRUNCH
ASLAN Pharmaceuticals announces first patient enrolled in global phase 2/3 study for varlitinib in gastric cancer
Varlitinib is a potent, reversible, small molecule pan-HER inhibitor and is currently being developed across multiple indications including biliary tract, gastric, metastatic breast and metastatic colorectal cancers.

ASLAN Pharmaceuticals, a biotech company focused on the development of immunotherapies and targeted agents for Asia prevalent tumour types, announced the enrolment of the first patient in a global phase 2/3 study investigating varlitinib as first line therapy in HER1/HER2 co-expressing advanced or metastatic gastric cancer patients.

Varlitinib is a potent, reversible, small molecule pan-HER inhibitor and is currently being developed across multiple indications including biliary tract, gastric, metastatic breast and metastatic colorectal cancers.

The global phase 2/3 study is a double blind, randomised two-arm study that aims to determine the efficacy of varlitinib in combination with mFOLFOX6 (a combination chemotherapy regimen) in comparison to mFOLFOX6 alone in the first-line setting. The first part of the study will enrol 40 HER1/HER2 coexpressing patients who were not exposed to prior systemic therapy and will read out in 2018.

Dr Bertil Lindmark, chief medical officer, ASLAN Pharmaceuticals, said: "This marks an important milestone for ASLAN as we treat the first patient in a further global late stage study of varlitinib, the second that we have initiated this year. Varlitinib has the potential to be an important first line therapeutic for metastatic or advance-stage gastric cancer patients who currently have very limited treatment options."

Gastric cancer currently ranks fourth in cancer incidence worldwide and is one of the most common types of cancer in Asia.

Varlitinib is also currently being investigated in a global pivotal trial in biliary tract cancer (BTC). Varlitinib has been awarded the Orphan Drug Designation (ODD) by the Korea MFDS for BTC. An ODD status was also granted by the US FDA for varlitinib in gastric cancer and cholangiocarcinoma.

Source: ASLAN Pharmaceuticals
NEWS CRUNCH  
news Shire, Microsoft and EURORDIS form Global Commission to accelerate time to diagnosis for children with rare diseases
news EmTech Asia explores future of life, humanity and economy
news Biology of Ageing II - Impactful Interventions
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  
COLUMNS  
Click here to receive APBN e-newsletters once a month!

APBN Editorial Calendar 2018
January:
Obesity / Outlook for 2018
February:
Searching for the fountain of youth
March:
Women in Science - Making a difference
April:
Digestive health in the 21st century - Trust your guts
May:
Dental health - The root to good health
June:
Cancer - Therapies and strategies for better patient outcomes
July:
Water management- Technologies for biotech and pharmaceutical industries
August:
Regenerative medicine / Biotech start ups
September:
Digital healthcare / 3D printing
October:
Bones / Breast cancer
November:
Liver health / Top science research nations & institutions
December:
AIDS / Breakthrough of the year/Emerging trends
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Lim Guan Yu
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2018 World Scientific Publishing Co Pte Ltd  •  Privacy Policy